# Bio-Reference Laboratories (BRLI) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BRLI
## Company Profile
- Ticker: BRLI
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States and has operated as a healthcare diagnostics business
- Tags: Diagnostics
## Stock Data
- Close: Not available
- Market cap: Not available
## Business Overview
### Diversified Healthcare and Diagnostics Platform
The source release primarily describes OPKO Health, a multinational biopharmaceutical and diagnostics company with laboratory services, specialty testing, commercial medicines, and multiple clinical-stage programs. BioReference-related diagnostics, commercial products, and the ModeX platform form its principal value drivers.
### Diagnostics Business
The diagnostics business includes core laboratory services and specialty tests such as the 4Kscore Test. BioReference provides an established clinical testing infrastructure alongside OPKO’s therapeutic activities.
### Commercial Medicines and Partner Economics
The pharmaceutical portfolio includes Rayaldee, profit-sharing economics from NGENLA, and products sold in international markets. Partnerships with companies including Lilly, Regeneron, and Nicoya add research funding, commercial opportunities, and potential milestone or royalty economics.
### ModeX Multispecific Antibody Platform
ModeX is a central source of pipeline innovation. Programs include antibody-targeted lipid nanoparticles for in vivo CAR T-cell generation, the MDX2003 tetraspecific T-cell engager-expander, and several Phase 1 assets focused on multispecific antibodies and immune-cell modulation.
## Why The Stock Is Moving

The latest monitored company update is “OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- ModeX plans to initiate a company-sponsored Phase 1 study of its in vivo CAR T program in autoimmune disease in late 2026 or early 2027.
- Enrollment in the MDX2301 Phase 1 study is expected to be completed in the third quarter of 2026, with initial data anticipated in late 2026 or early 2027.

## Recent News
- 2026-08-13 13:15 EST — [OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests](https://biopharmsignal.com/news/BRLI/opko-health-expands-strategic-relationship-with-healthcare-royalty-through-125-m-ea1a2899) — Source: Bio-Reference Laboratories
- 2026-07-27 20:05 EST — [OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results](https://biopharmsignal.com/news/BRLI/opko-health-reports-second-quarter-2026-business-highlights-and-financial-result-2ac27e11) — Source: Bio-Reference Laboratories
- 2026-07-23 16:30 EST — [OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026](https://biopharmsignal.com/news/BRLI/opko-health-to-report-second-quarter-2026-financial-results-on-july-27-2026-4b38e04c) — Source: Bio-Reference Laboratories
- 2026-06-15 12:00 EST — [Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026](https://biopharmsignal.com/news/BRLI/preclinical-data-for-opko-biologics-opk8801001-in-acromegaly-presented-at-endo-2-5e19f000) — Source: Bio-Reference Laboratories
- 2026-04-30 12:30 EST — [OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China](https://biopharmsignal.com/news/BRLI/opko-health-expands-nicoya-agreement-to-support-rayaldeer-commercialization-in-greater-china) — Source: Bio-Reference Laboratories